Experimental eye injection aims to slow vision loss in rare disease
NCT ID NCT06292650
First seen Jan 08, 2026 · Last updated Jun 18, 2026 · Updated 29 times
Summary
This early-stage trial tests the safety of a new drug called ZM-02, given as an injection into one eye, in 12 adults with retinitis pigmentosa—a genetic condition that causes gradual vision loss. The main goal is to check for side effects, not to cure the disease. Researchers will also measure if the injection helps patients see better in dim light.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Beijing Tongren Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.